Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma

被引：90
作者：
Ganatra, Sarju [1 ,2 ,5 ]
Redd, Robert [3 ]
Hayek, Salim S. [6 ]
Parikh, Rohan [1 ]
Azam, Tariq [6 ]
Yanik, Gregory A. [7 ]
Spendley, Lauren [4 ]
Nikiforow, Sarah [4 ]
Jacobson, Caron [4 ]
Nohria, Anju [2 ,5 ]
机构：
[1] Lahey Hosp & Med Ctr, Dept Med, Div Cardiovasc Med, Burlington, MA USA
[2] Dana Farber Canc Inst, Adult Canc Survivorship Program, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Div Cardiovasc Med, Cardiooncol Program, 75 Francis St, Boston, MA 02115 USA
[6] Univ Michigan, Div Cardiol, Ann Arbor, MI 48109 USA
[7] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA
来源：
CIRCULATION | 2020年 / 142卷 / 17期
关键词：
axicabtagene ciloleucel; chimeric antigen receptor T-cell therapy; cardiomyopathy; cardiotoxicity; cytokine release syndrome; heart failure; lymphoma; non-Hodgkin; receptors; chimeric antigen; tisagenlecleucel;
D O I：
10.1161/CIRCULATIONAHA.120.048100
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1687 / 1690
页数：4
相关论文
共 50 条
  • [21] Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy
    Gill, Jashan
    CURRENT CARDIOLOGY REVIEWS, 2023, 19 (01) : 54 - 54
  • [22] Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options
    Toro-Mijares, Raul Del
    Oluwole, Olalekan
    Jayani, Reena V.
    Kassim, Adetola A.
    Savani, Bipin N.
    Dholaria, Bhagirathbhai
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (01) : 15 - 24
  • [23] Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
    Makita, Shinichi
    Yoshimura, Kiyoshi
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (06) : 1109 - 1118
  • [24] Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
    Reinhardt, Bryanna
    Lee, Patrick
    Sasine, Joshua P. P.
    CELLS, 2023, 12 (04)
  • [25] ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma
    Choi, CW
    Paek, CW
    Seo, JH
    Kim, BS
    Shin, SW
    Kim, YH
    Kim, JS
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2002, 17 (05) : 621 - 624
  • [26] A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
    Atrash, Shebli
    Moyo, Tamara K.
    ONCOTARGETS AND THERAPY, 2021, 14 : 2185 - 2201
  • [27] Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products
    Hunter, Bradley D.
    Rogalski, Michael
    Jacobson, Caron A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1157 - 1164
  • [28] Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma
    Paolo Strati
    Sattva S. Neelapu
    Current Oncology Reports, 2019, 21
  • [29] Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma
    Zhou, Dian
    Wang, Ying
    Cheng, Hai
    Zhu, Lili
    Chen, Wei
    Li, Hujun
    Zhang, Xiaotian
    Xia, Jieyun
    Qi, Yuekun
    Ma, Sha
    Zhu, Feng
    Yan, Zhiling
    Qi, Kunming
    Sang, Wei
    Sun, Haiying
    Li, Depeng
    Cao, Jiang
    Li, Zhenyu
    Xu, Kailin
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2023, 29 (02) : 179 - 185
  • [30] Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
    Lyman, Gary H.
    Nguyen, Andy
    Snyder, Sophie
    Gitlin, Matthew
    Chung, Karen C.
    JAMA NETWORK OPEN, 2020, 3 (04) : E202072
12345